1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-E386.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
3. Abnet CC, Arnold M, Wei WQ. Epidemiology of oesophageal squa- mous cell carcinoma. Gastroenterology. 2018;154:360-373.
4. Rustgi AK, El-Serag HB. Oesophageal carcinoma. N Engl J Med. 2014;371:2499-2509.
5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7-30.
6. Kuwano H, Nishimura Y, Oyama T, et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus april 2012 edited by the Japan oesophageal society. Esophagus. 2015;12:1-30.
7. Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oe- sophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol. 2017;18:631-639.
8. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
9. Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemo- therapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:1506-1517.
10. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembroli- zumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789-1801.
11. Robert C, Schachter J, Long GV, et al. Pembrolizumab ver- sus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521-2532.
12. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378:2078-2092.
13. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemo- therapy for squamous non–small-cell lung cancer. N Engl J Med. 2018;379:2040-2051.
14. Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recur- rent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856-1867.
15. Shields BD, Mahmoud F, Taylor EM, et al. Indicators of responsive- ness to immune checkpoint inhibitors. Sci Rep. 2017;7:807.
16. Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti– PD-1/PD-L1. Clin Cancer Res. 2017;23:1920-1928.
17. Kim MY, Koh J, Kim S, Go H, Jeon YK, Chung DH. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: comparison with tumor-infiltrating T cells and the status of oncogenic drivers. Lung Cancer. 2015;88:24-33.
18. De Meulenaere A, Vermassen T, Creytens D, et al. Importance of choice of materials and methods in PD-L1 and TIL assess- ment in oropharyngeal squamous cell carcinoma. Histopathology. 2018;73:500-509.
19. Rizvi H, Sanchez-Vega F, La K, et al. Molecular determinants of re- sponse to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol. 2018;36:633-641.
20. Wargo JA, Reddy SM, Reuben A, Sharma P. Monitoring immune responses in the tumour microenvironment. Curr Opin Immunol. 2016;41:23-31.
21. Gujar S, Pol JG, Kroemer G. Heating it up: oncolytic viruses make tumours 'hot' and suitable for checkpoint blockade immunothera- pies. Oncoimmunology. 2018;7:e1442169.
22. Gottfried E, Kreutz M, Mackensen A. Tumor metabolism as modula- tor of immune response and tumour progression. Semin Cancer Biol. 2012;22:335-341.
23. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic im- portance of the standardized uptake value on (18)F-fluoro-2-deoxy- glucose-positron emission tomography scan in non–small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999;17:3201-3206.
24. Kaira K, Endo M, Abe M, et al. Biologic correlation of 2-[18F]-fluoro- 2-deoxy-D-glucose uptake on positron emission tomography in thy- mic epithelial tumours. J Clin Oncol. 2010;28:3746-3753.
25. Kasahara N, Kaira K, Bao P, et al. Correlation of tumour-related im- munity with 18F-FDG-PET in pulmonary squamous-cell carcinoma. Lung Cancer. 2018;119:71-77.
26. Kaira K, Shimizu K, Kitahara S, et al. 2-Deoxy-2-[fluorine-18] fluo- ro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pul- monary adenocarcinoma. Eur J Cancer. 2018;101:181-190.
27. Heiden BT, Patel N, Nancarrow DJ, et al. Positron emission tomog- raphy 18F-fluorodeoxyglucose uptake correlates with KRAS and EMT gene signatures in operable oesophageal adenocarcinoma. J Surg Res. 2018;232:621-628.
28. Tomiyoshi K, Amed K, Muhammad S, et al. Synthesis of isomers of 18F-labelled amino acid radiopharmaceutical: position 2- and 3-L-18F-alpha-methyltyrosine using a separation and purification system. Nucl Med Commun. 1997;18:169-175.
29. Sohda M, Kato H, Suzuki S, et al. 18F-FAMT-PET is useful for the diagnosis of lymph node metastasis in operable oesophageal squa- mous cell carcinoma. Ann Surg Oncol. 2010;17:3181-3186.
30. Suzuki S, Kaira K, Ohshima Y, et al. Biological significance of flu- orine-18-alpha-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer. Br J Cancer. 2014;110:1985-1991.
31. Honjo H, Toh Y, Sohda M, et al. Clinical significance and pheno- type of MTA1 expression in oesophageal squamous cell carcinoma. Anticancer Res. 2017;37:4147-4155.
32. Oriuchi N, Tomiyoshi K, Inoue T, et al. Independent thallium-201 accumulation and fluorine-18-fluorodeoxyglucose metabolism in glioma. J Nucl Med. 1996;37:457-462.
33. Shah MA, Kojima T, Hochhauser D, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the Phase 2 KEYNOTE-180 Study. JAMA Oncol. 2019;5:546-550.
34. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
35. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipili- mumab in lung cancer with a high tumour mutational burden. N Engl J Med. 2018;378:2093-2104.
36. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non–small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837-1846.
37. Ayers M, Lunceford J, Nebozhyn M, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930-2940.
38. Li M, Li A, Zhou S, et al. Heterogeneity of PD-L1 expression in pri- mary tumours and paired lymph node metastases of triple negative breast cancer. BMC Cancer. 2018;18:4.
39. Jilaveanu LB, Shuch B, Zito CR, et al. PD-L1 expression in clear cell renal cell carcinoma: an analysis of nephrectomy and sites of metas- tases. J Cancer. 2014;5:166-172.
40. Mukherji D, Jabbour MN, Saroufim M, et al. Programmed death- ligand 1 expression in muscle-invasive bladder cancer cystectomy specimens and lymph node metastasis: a reliable treatment selec- tion biomarker?Clin Genitourin Cancer. 2016;14:183-187.
41. Mueckler M, Thorens B. The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013;34:121-138.
42. Blayney JK, Cairns L, Li G, et al. Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma. Oncotarget. 2018;9:18518-18528.
43. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 1998;273:23629-23632.
44. Nakanishi K, Ogata S, Matsuo H, et al. Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper uri- nary tract. Virchows Arch. 2007;451:681-690.
45. Nawashiro H, Otani N, Shinomiya N, et al. L-type amino acid trans- porter 1 as a potential molecular target in human astrocytic tu- mours. Int J Cancer. 2006;119:484-492.
46. Ichinoe M, Mikami T, Yoshida T, et al. High expression of L-type ami- no-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non–cancerous lesions. Pathol Int. 2011;61:281-289.
47. Kaira K, Serizawa M, Koh Y, et al. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur J Cancer. 2012;48:1244-1254.
48. Wiriyasermkul P, Nagamori S, Tominaga H, et al. Transport of 3-flu- oro-L-alpha-methyl-tyrosine by tumour-upregulated L-type amino acid transporter 1: a cause of the tumour uptake in PET. J Nucl Med. 2012;53:1253-1261.
49. Kaira K, Oriuchi N, Otani Y, et al. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung can- cer: a clinicopathologic study. Clin Cancer Res. 2007;13:6369-6378.
50. Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime?Semin Cancer Biol. 2005;15:254-266.
51. Düvel K, Yecies JL, Menon S, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010;39:171-183.
52. Koh MY, Powis G. Passing the baton: the HIF switch. Trends Biochem Sci. 2012;37:364-372.
53. Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC- mediated T cell activation. J Exp Med. 2014;211:781-790.
54. Chen J, Jiang CC, Jin L, Zhang XD. Regulation of PD-L1: a novel role of pro–survival signalling in cancer. Ann Oncol. 2016;27:409-416.
55. Ji M, Liu Y, Li Q, et al. PD-1/PD-L1 pathway in non–small-cell lung cancer and its relation with EGFR mutation. J Transl Med. 2015;13:5.
56. Takada K, Okamoto T, Toyokawa G, et al. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma. Lung Cancer. 2017;104:7-15.
57. Koh YW, Lee SJ, Han JH, Haam S, Jung J, Lee HW. PD-L1 protein ex- pression in non–small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: a study based on immunohisto- chemistry and RNA sequencing data. Lung Cancer. 2019;129:41-47.
58. Xue S, Hu M, Li P, et al. Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma. Oncotarget. 2017;8:49702-49712.
59. Wang Q, Holst J. L-type amino acid transport and cancer: target- ing the mTORC1 pathway to inhibit neoplasia. Am J Cancer Res. 2015;5:1281-1294.
60. Vécsei L, Szalárdy L, Fülöp F, Toldi J. Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov. 2013;12:64-82.